rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Moleculin Biotech, Inc.

MBRX · Nasdaq

Health CareBiotechnologyNot moving yet

MBRX stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 83.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
18 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$337KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Donald H. PickerChief Science Officerbought173,3333 Aug 2026filed 5 Aug 2026
Donald H. PickerChief Science Officerbought519,9993 Aug 2026filed 5 Aug 2026
Walter V. KlempCEO and Presidentbought533,3333 Aug 2026filed 5 Aug 2026
Jonathan P. FosterChief Financial Officerbought293,3333 Aug 2026filed 5 Aug 2026
Jonathan P. FosterChief Financial Officerbought879,9993 Aug 2026filed 5 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders18-1 on the quarter
New · exited5 · 6
Reported value$519K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202647,252$132K+14,923+46.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202642,215$118K+28,346+204.4%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202629,883$83K+23,811+392.1%
XTX Topco Ltdnew · filed 14 Aug 202622,942$64K+22,942
MORGAN STANLEYadded · filed 13 Aug 202620,036$56K+20,000+55555.6%
Rockefeller Capital Management L.P.added · filed 13 Aug 202615,000$42K+10,579+239.3%
Tower Research Capital LLC (TRC)added · filed 11 Aug 20263,514$9,804+1,679+91.5%
CITIGROUP INCnew · filed 3 Aug 20262,674$7,460+2,674
BARCLAYS PLCnew · filed 14 Aug 2026621$1,733+621
BlackRock, Inc.unchanged · filed 7 Aug 2026491$1,37000.0%
31 Mar 2024 – 30 Jun 2026
151922Mar 24Sep 24Jun 25Dec 25Jun 26

Everyone who traded it

Donald H. Picker Company insiderChief Science Officer · last 15 Oct 20261 · 0
Jonathan P. Foster Company insiderChief Financial Officer · last 15 Oct 20264 · 0
Walter Klemp V Company insiderCEO and President · last 15 Oct 20268 · 1
Elizabeth Cermak Company insiderDirector · last 12 Nov 20250 · 0
John M. Climaco Company insiderDirector · last 12 Nov 20250 · 0
Joy Yan Company insiderDirector · last 12 Nov 20250 · 0
Michael D. Cannon Company insiderDirector · last 12 Nov 20250 · 0
Robert E. George Company insiderDirector · last 12 Nov 20252 · 0
Waldemar Priebe Company insider10% owner · last 20 Aug 20200 · 1
Jacqueline Northcut Company insiderDirector · last 5 May 20171 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-164%
Share count trendFY 2025 · to 11 Mar 202666.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$8.9M
Free cash flowFY 2025 · to 31 Dec 2025−$22.7M

Analyst forecasts

No analyst forecasts yet.